Antistaphylococcal discovery pipeline; where are we now?
Jazyk angličtina Země Francie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
38219657
DOI
10.1016/j.ejmech.2023.116077
PII: S0223-5234(23)01044-9
Knihovny.cz E-zdroje
- Klíčová slova
- Antibody, Antistaphylococcal, Clinical trial, Drug discovery, Small molecules,
- MeSH
- antibakteriální látky * farmakologie terapeutické užití MeSH
- lidé MeSH
- peptidy terapeutické užití MeSH
- stafylokokové infekce * farmakoterapie MeSH
- Staphylococcus aureus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- antibakteriální látky * MeSH
- peptidy MeSH
The serious spread of antibiotic-resistant Staphylococcal aureus strains is alarming. This is reflected by the measures governments and health-related bodies are offering to ease antibiotic drug development. Finding new active agents, preferably with novel mechanism of action, or even finding new targets for drug development are essential. In this review, we summarize the current status of novel antistaphylococcal agents undergoing clinical trials. We mainly discuss antistaphylococcal small molecules and peptides in the text with a special focus on their chemistry, while antistaphylococcal immunotherapy (antibodies) are mentioned in a summative table. This review shall serve as a summary that influences future synthetic efforts in the antistaphyloccocals development field.
Citace poskytuje Crossref.org
